Sontuzumab is a humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1). Sontuzumab binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells.